Filing Flows

Filing Flows › biote (BTMD) › Q2 2026 › vs Q1 2026

biote (BTMD) Q2 2026 vs Q1 2026 (quarter over quarter)

biote's revenue fell $703K (-2%) from $44.9M in Q1 2026 to $44.2M in Q2 2026. The biggest changes: Product Revenue −$514K (-1%); Service Revenue −$189K (-18%).

biote, Q2 2026: revenue $44.2M (-10% year over year), operating margin -7.9%, net loss $7.4M, operating cash flow −$1.2M. The chart draws each line against Q1 2026, the increases inside each band.

biote: what changed, Q2 2026 vs Q1 2026biote: what changed, Q2 2026 vs Q1 2026Net loss$10.1MOperating cash sources$10.1MNet loss absorbed$10.1MCosts & expenses$6.6MOperating costs$6.0MCash used in operations$5.1MWorking capital & other$4.8MSG&A$4.6MInterest & other, net$3.8MCost of revenue$1.3M

Every line

LineQ2 2026Q1 2026Change%
Pellet Procedures Product Revenue$30.3M$31.3M−$986K-3%
Dietary Supplements$11.4M$11.0M$320K+3%
Disposable Trocars Product Revenue$1.2M$1.1M$81K+7%
Shipping Fees and Other Product Revenue$505K$434K$71K+16%
Other Service Revenue$406K$578K−$172K-30%
Contract Term Services Revenue$311K$332K−$21K-6%
Training Service Revenue$134K$130K$4K+3%
Product Revenue$43.4M$43.9M−$514K-1%
Service Revenue$851K$1.0M−$189K-18%
Revenue$44.2M$44.9M−$703K-2%
Net loss$7.4M−$2.7M$10.1M—
Costs & expenses$51.7M$45.1M$6.6M+15%
Operating costs$47.7M$41.8M$6.0M+14%
Interest & other, net$3.6M−$172K$3.8M—
Income tax$296K$662K−$366K-55%
Cost of revenue$15.3M$14.0M$1.3M+10%
SG&A$32.4M$27.8M$4.6M+17%
Operating cash sources$7.4M−$2.7M$10.1M—
Depreciation & amortization$963K$980K−$17K-2%
Share-based compensation$2.0M$1.8M$212K+12%
Working capital & other$3.3M−$1.5M$4.8M—
Cash used in operations$1.2M−$3.9M$5.1M—
Net loss absorbed$7.4M−$2.7M$10.1M—

Questions

How much did biote's revenue grow quarter over quarter in Q2 2026?

biote's revenue fell $703K (-2%) from $44.9M in Q1 2026 to $44.2M in Q2 2026.

What drove biote's revenue change in Q2 2026?

Product Revenue −$514K (-1%); Service Revenue −$189K (-18%).

Q2 2026 results → · Compare in the interactive Sankey →